Compare NVO & NEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVO | NEM |
|---|---|---|
| Founded | 1923 | 1916 |
| Country | Denmark | United States |
| Employees | 69500 | 17500 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.5B | 138.7B |
| IPO Year | N/A | N/A |
| Metric | NVO | NEM |
|---|---|---|
| Price | $38.51 | $109.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $51.00 | ★ $113.50 |
| AVG Volume (30 Days) | ★ 19.4M | 7.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.24% | 0.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.18 |
| Revenue Next Year | $3.30 | $4.04 |
| P/E Ratio | ★ $13.60 | $19.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.85 | $42.93 |
| 52 Week High | $82.23 | $134.88 |
| Indicator | NVO | NEM |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 38.67 |
| Support Level | $35.85 | $108.05 |
| Resistance Level | $39.88 | $131.40 |
| Average True Range (ATR) | 0.87 | 4.24 |
| MACD | 0.43 | -1.79 |
| Stochastic Oscillator | 66.00 | 6.49 |
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 11 mines and interests in two joint ventures in the Americas, Africa, Australia, and Papua New Guinea. The company is expected to sell roughly 5.6 million ounces of gold in 2025 from its core mines after selling six higher-cost, smaller mines following the Newcrest acquisition. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves, along with significant byproduct reserves at the end of December 2024.